Several gene therapy applications require the transfer and simultaneous expression of multiple genes in the same cell. In this study, we analyzed the potential for coordinated expression of an endogenous bidirectional promoter located on chromosome X, which controls the expression of the heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2) and alpha-galactosidase (GLA) genes. The promoter was cloned in both transcriptional orientations in a foamy virus (FV) vector backbone, whereas the enhanced green fluorescent protein (EGFP) and low-affinity nerve growth factor receptor (DLNGFR) reporter genes were cloned in the 5 0 -3 0 and 3 0 -5 0 transcriptional orientations, respectively. In all the cell lines tested, both vectors showed high levels of transgene coexpression that reached 76% of total positive cells (range from 76 to 18%). Comparison of EGFP and DNGFR levels revealed that the side of the promoter that drives the expression of the HNRNPH2 gene in the genome was stronger and in accordance to its in situ activity. When tested with CD34 + cells, transgene coexpression reached 35.3% of all positive cells in progenitor assays and 16.8% of all positive cells after transplantation in NOD/severe combined immunodeficient mice. In summary, we show that the endogenous promoter used in this study holds bidirectional activity in the context of FV vectors and can be used in gene therapy applications requiring synchronized expression of two genes.
Introduction
The expression of multiple genes in gene transfer applications is a desirable property of viral vectors. Coexpression of a marker gene or an antibiotic resistance gene could be used to enrich gene-corrected cells before their in vivo administration. In applications in which regulated gene expression is required, co-delivery of a transcriptional activator or repressor to the same target cell could also be a useful feature of any vector design. In vivo selection of transduced cells can also be carried out by concomitant expression of the MGMT gene. [1] [2] [3] [4] [5] Finally, the phenomenon of vector-mediated insertional mutagenesis could be tackled by simultaneous expression of conditionally cytotoxic genes.
A number of approaches have been used to generate bicistronic vectors capable of simultaneous transgene expression. A widely used method is the inclusion of viral internal ribosome entry site (IRES) elements that permit cap-independent mRNA translation. However, this technology has been characterized by reduced expression of the transgene downstream of the IRES element and cell type-dependent efficiency of balanced expression. [6] [7] [8] Another method has been the construction of viral vectors with two transcription units cloned in tandem but this design has been characterized by transcriptional interference. 9, 10 This strategy has also been exploited in lentiviral vectors, but the published reports present conflicting data on the problem of promoter interference. 11, 12 Expression of multiple genes by a single vector can also be accomplished with artificial genes encoding multiple proteins linked by the 2A sequences of the foot-and-mouth disease virus in which cleavage of the expressed polyproteins is mediated by the 2A peptides. [13] [14] [15] [16] However, addition of the 2A peptide requires engineering of the proteins, although the expression of the cDNAs has been reported to be dependent on the nature of the expressed genes and the cloning order in the construct. 3 Coordinated expression has also been achieved with the construction of a synthetic bidirectional promoter using elements from the viral CMV, the UBI-C and the PGK promoter sequences. 17 Recently, a ubiquitously acting chromatin opening element (A2UCOE), located between the divergently transcribed heterogeneous nuclear ribonucleoprotein H2 (HNRPA2B1) and CBX3 genes, has shown more stable and position-independent expression compared with viral promoters. 18 The A2UCOE element is a methylation-free CpG island that is present in divergently transcribed housekeeping genes, but it has not been tested for its bidirectional promoter activity in vitro.
Computational studies have identified a large number of divergently transcribed gene pairs, representing about 10% of all human genes, located on opposite strands with transcriptional start sites o1000 bp apart. [19] [20] [21] The transcripts of many bidirectional gene pairs were simultaneously coexpressed, indicating that their shared cis-regulatory elements could initiate transcription at both directions. 21 This bidirectional regulation system has been observed in the mammalian genome and it may reflect the requirement for tightly coordinated expression in certain cellular pathways, such as cell cycle, 22 histone gene expression 23 and heat shock responses. 24 Such dual promoters are theoretically less likely to activate transgene silencing as they are often driving the expression of housekeeping genes. 21 In this study, we have used such a putative bidirectional promoter which was identified in the course of a gene targeting experiment (DW Russell, unpublished data) and is located on chromosome Xq22.1. The promoter is driving the expression of the HNRNPH2 and the alpha-galactosidase (GLA) human genes, which are expressed in many tissues, including the hematopoietic system (HNRNPH2 (http://genome.ucsc.edu/ cgi-bin/hgTracks?db=hg18&position=chrX:100549847-100555773&hgsid=146016699&knownGene=full); GLA (http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg18& position=chrX:100539435-100549657&hgsid=146016699& knownGene=full)). We show that when cloned in a foamy virus (FV) vector backbone, the promoter holds bidirectional activity and can transcribe two reporter genes in a coordinated manner, recapitulating its endogenous activity.
Results

Both promoter orientations are active in diverse cellular environments
The putative bidirectional promoter, located at chromosome position Xq22.1, lies in the intragenic region between the GLA (NM_000169.2) and the HNRNPH2 genes (NM_001032393.1) (Figure 1a ). The sequence was 402 bp long and included the region immediately upstream of the translation start site of the GLA gene and part of the HNRPH2 5 0 -untranslated region up to position +103 of the mRNA. The promoter was PCR isolated from human genomic DNA and cloned in an intermediate vector (see Materials and methods) from which it was further amplified with primers carrying ClaI or AgeI restriction enzyme sites, fitted to permit directional cloning into a deleted FV vector with an enhanced green fluorescent protein (EGFP) reporter gene ( Figure 1b) . The constructs were designated DF.GH.F and DF.HG.F to mark the sequence orientation towards the HNRNPH2 or the GLA gene respectively, followed by the EGFP gene (F). The mean titer for the vector (expressed as EGFP-transducing particles per ml of non-concentrated supernatant) with the GH orientation was 5 Â 10E5 (n ¼ 3), whereas the titer with the HG orientation was 3.3 Â 10E5 (n ¼ 3). The vectors showed high titers as those obtained with standard FV vectors with constitutive promoters, indicating that the inserted sequence did not exert any deleterious effect on viral vector packaging. To test whether the cloned sequence provided adequate promoter activity, we transduced HT1080 cells with the DF.HG.F, DF.GH.F and DF.PGK.EGFP vectors at similar multiplicity of infections (MOIs) (2.1, 3.0 and 2.5, respectively) and analyzed EGFP expression levels by flow cytometry. Transgene expression could be detected in cells transduced with either DF.GH.F or DF.HG.F vectors; in addition, it seems that the GH promoter has reasonable expression levels that can be compared with those obtained with the PGK To test the ability of the bidirectional promoter to drive the simultaneous expression of two transgenes, we cloned each orientation of the promoter in a dual reporter FV backbone that had the deleted low-affinity nerve growth factor receptor (DLNGFR) with a rabbit b-globin polyA upstream and the EGFP reporter downstream of the promoter sequence ( Figure 2a ). These vectors were designated DFN.HG.F and DFN.GH.F and were produced at high titers; concentrated vector stock titers were 3.24 ± 1.33 Â 10 6 TU ml À1 (n ¼ 20) for DFN. HG.F and 3.4±2 Â 10 6 TU ml À1 (n ¼ 12) for DFN.GH. 
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The bidirectional promoter was efficient in driving the simultaneous expression of both transgenes in the epithelial (HeLa, 293T, HT1080 and BHK), neuroblastoma (Neuro-2A and SHSY5Y) and hematopoietic cell lines (MEL and HEL). Overall, the dual promoter was active in both directions (DFN.HG.F and DFN.GH.F) as indicated by similar percentages of double-positive cells. In three out of eight cell lines (293T, BHK and HEL) the DFN.HG.F vector gave statistically significant (Po0.05) higher numbers of positive cells coexpressing the two transgenes compared with the DFN.GH.F vector ( Figure  2b) . A pattern of balanced expression was more evident in the epithelial cells compared with hematopoietic or neuroblastoma lines, with 460% of total positive cells coexpressing both EGFP and DLNGFR. These results indicate that the promoter showed bidirectional activity that was significantly pronounced in epithelial cell lines.
To assay for transgene expression levels, we calculated the total EGFP MFI for each vector in each cell line transduced at similar MOIs (range 1-4). As shown in Figure 2c , in three (HT1080, BHK and HEL) out of eight cell lines, a higher EGFP MFI was observed with the DFN.GH.F vector (Po0.05) indicating that the HNRNPH2 side of the promoter, which drives EGFP expression in this vector, is stronger in these cell lines. No particular differences were observed for the DLNGFR MFI between DFN.HG.F and DFN.GH.F vectors (data not shown). To confirm that the higher EGFP MFI observed with the DFN.GH.F vector was due to transcription imbalances between the two promoter sides rather than copy number variations, we determined the vector copy number by Taqman PCR in three cell lines (HeLa, 293T and HT1080). Expression of EGFP was then corrected for vector copy number and plotted in Figure 2d . The results show that in HT1080 cells, there is a clear bias of the GH promoter orientation, which is less prominent in HeLa and absent in 293T cells ( Figure  2d ). This indicated that the HNRNPH2 side of the promoter has stronger activity in this cell line and suggested that vector performance is, to some extent, cell line dependent.
In vitro transduction of primary hematopoietic stem/ progenitor cells by FV vectors carrying the bidirectional promoter
We subsequently assessed the expression efficiency of the bidirectional promoter in primary human cord blood (CB) CD34 + cells by transducing them ex vivo with DFN.HG.F and DFN.GH.F vectors at MOI 20 in serumfree medium supplemented with cytokines, as described in the Materials and methods section. Each CD34 + sample was transduced in parallel with both vectors to facilitate direct comparison. Transgene expression was analyzed by flow cytometry 5-7 days after transduction in cell pools expanded in liquid cultures. We also analyzed the efficiency of the dual promoter on human short-term hematopoietic progenitors in methylcellulose cultures scored at 10 days after transduction. Overall, DFN.HG. (Figure 3c ), but owing to extensive variability, the difference from the values obtained with DFN.HG.F vector was not significant (P ¼ 0.14). In contrast to EGFP, no differences in the total DLNGFR MFI ( Figure 3d) were detected between the two vectors, but this could be attributed to the nature of the DLNGFR protein or the different detection method. These findings were in accordance with what we had observed in the cell lines strongly indicating that the HNRNPH2 side of the promoter (DFN.GH.F vector) was also more potent in human hematopoietic stem cells (HSCs).
DFN.GH.F vector
Dual expression by the bidirectional promoter in NOD/SCID repopulating cells
To test the long-term expression efficiency of the bidirectional promoter, we performed NOD/severe combined immunodeficient (SCID) bone marrow transplantation experiments with human CB CD34 + cells transduced with DFN.HG.F or DFN.GH.F FV vectors at MOI 20 as mentioned in the previous section. Busulfanconditioned animals receiving transduced cells were analyzed 8-10 weeks after transplantation for the presence of human multilineage hematopoiesis in their bone marrow by flow cytometry. Human cell engraftment levels, as measured by the percentage of human CD45 + cells in the bone marrow, ranged from 0.1 to 94% of total cells depending on the conditioning regime and were unaffected by the vector used to transduce the transplanted cells (data not shown). We observed a mean of 16.8% (range 3.7-27.5%) and 13.6% (range 6.3-28%) of total human positive cells coexpressing EGFP and DLNGFR, with DFN.HG.F and DFN.GH.F vectors, respectively (P40.3) (Figure 4a ), originating from SCID repopulating cells containing comparable vector copies (average vector copy number: DFN.HG.F: 2.6; DFN.GH.F: 2). Both promoter orientations were active in the engrafted human cell population, whereas the total EGFP and DLNGFR MFI comparison reproduced the pattern observed for human HSCs in vitro. Specifically, the DFN.GH.F vector produced higher EGFP MFI compared with the DFN.HG.F vector (Figure 4b ), although comparable levels of DLNGFR were seen with either vector (P40.5) (Figure 4c 
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The bidirectional promoter retains its in situ transcriptional activity in the foamy vector
Overall, our gene transfer results with the bidirectional promoter from diverse cellular backgrounds indicate that the side of the promoter that drives transcription of HNRNPH2 gene in the genome is stronger. To investigate whether the dual promoter has retained its in situ activity when introduced randomly in the genome with an FV vector, we examined the mRNA expression levels of HNRNPH2 and GLA genes in the same cell lines used for gene transfer using a real-time PCR assay. As seen in Figure 5 , a o1 relative expression ratio of GLA over HNRNPH2 was seen in the majority of the cells tested, indicating that these cells expressed higher mRNA levels of HNRNPH2 compared with GLA. Similar results were also obtained for human CB CD34 + , implying that the transcriptional activity of the dual promoter in its genomic locus is also biased towards the HNRNPH2 gene. These results are in accordance with our EGFP transgene expression data, denoting that the transcriptional activity of the dual promoter in situ is reproduced when the latter was transferred into a cell in the context of an FV vector.
Discussion
There are B1500 divergently transcribed gene pairs in the genome indicating the existence of numerous putative bidirectional promoters. 25, 26 Promoters capable of simultaneous transcription by RNA polymerases II and III have also been identified, which could be used for transgene and short hairpin RNA expression by a single vector. 27 The widespread occurrence of such promoters probably reflects the requirement for tightly regulated gene expression. Such endogenous promoters should follow tissue-specific expression pattern and should offer a useful tool for selecting endogenous putative dual promoters with a particular tissue or cell specificity.
In this report, we describe a novel retroviral vector based on a deleted FV backbone that has the ability to express two cDNAs in a coordinated manner. This was accomplished with the use of an endogenous human promoter that is located on chromosome X, in the intragenic region between the GLA and the HNRNPH2 genes. We initially confirmed its bidirectional activity in a FV vector with a single reporter (EGFP) by cloning the promoter in either orientation. Both orientations of the promoter proved functional in various cell types transduced at low MOIs, with a propensity for superior efficiency in epithelial cells, denoting nonetheless its potential use in gene transfer applications. The promoter retained its activity regardless of its orientation in the FV vector. In a variety of cell lines, including mouse HSCs, the EGFP levels obtained with the bidirectional promoter as determined by MFI reached 20-70% of the MFI values seen with a standard PGK promoter.
We then assayed the ability of the promoter to drive the simultaneous expression of a pair of reporter genes cloned on either side, as similar endogenous promoters located between divergently transcribed genes often express the two genes in a discordant manner. 21 We cloned the promoter in a FV vector carrying the EGFP and the DLNGFR reporters and we calculated the number of double positive over the total number of transgene-positive cells. Our results showed that the promoter retained its intrinsic bidirectional activity in most of the lines tested and the expression of the two transgenes was coordinately regulated. The dual promoter also proved functional, although slightly less efficient, in human HSCs with 35% of total positive cells coexpressing both transgenes when transduced with the DFN.HG.F vector. Both sides of the promoter were active in SCID repopulating cells, with an average of 16% total positive human cells coexpressing EGFP and DLNGFR. Interestingly, the efficiency of the vector in the different hematopoietic lineages in our xenotransplantation model proved comparable with the results seen in mouse HSCs with a recently reported ubiquitously acting chromatinopening element (UCOE) element. 18 It is noteworthy that these levels were achieved with low vector copy numbers (B2), minimizing the risk for insertional mutagenesis. Importantly, stable expression of the two transgenes was observed after hematopoietic cell differentiation in vitro and in vivo, indicating not only that the promoter was not being silenced but also that divergent transcription remained unaltered through this process.
Comparison of promoter activity strength between the two vectors (DFN.GH.F and DFN.HG.F) was evaluated by scoring for total EGFP MFI; the promoter produced higher detectable levels of EGFP in the DFN.GH.F vector, indicating that the direction that drives the expression of the HNRNPH2 gene in the genome was relatively stronger. Particularly, in HT1080, BHK and HEL cells, the effect was more pronounced and gave statistically significant deviations. This effect, however, was clearly cell line-dependent and not due to copy number variations. The enhanced activity of the HNRNPH2 side of the dual promoter was also observed in human HSCs and SCID repopulating cells. The fact that no such increase was observed when DLNGFR expression was evaluated (in the DFN.HG.F vector) most likely reflects the nature of the latter protein and possible limitations of Foamy viral vectors with a bidirectional promoter A Andrianaki et al its detection method. However, when we tested for mRNA levels of the endogenous linked genes, we also observed higher levels of HNRNPH2 RNA, indicating that our vector-transferred promoter recapitulated its endogenous operational mode. This is an important feature of the vector as one can correctly predict the activity of the dual promoter by measuring the respective GLA and HNRNPH2 levels in the cells of choice.
Viral vector-mediated gene transfer into hematopoietic stem cells has proved a promising tool for the treatment of life-threatening hematological genetic disorders. However, following adverse reactions from gene therapy trials, 28, 29 the problem of insertional mutagenesis in gene transfer applications has become a priority. Dual expression vectors offer the possibility of combined gene expression from a single provirus, thus cutting the risk of provirus-mediated transformation. FV vectors are attractive vehicles for gene transfer as they can efficiently transduce quiescent cells, including SCID repopulating cells, with minor transgene silencing [30] [31] [32] and readthrough transcription. 33 So far, few studies have used endogenous promoters for gene transfer applications probably due to their reduced strength compared with viral ones. Ongoing evidence, however, suggests that low transgene expression may be sufficient for particular applications of gene therapy. 34, 35 Synthetic bidirectional promoters are attractive and probably stronger alternatives to endogenous ones, but promoter interference may impair the expression of adjacent transcription units placed in the same vector. 12 Endogenous promoters on the other hand have evolved with a built-in capacity for simultaneous expression of the linked genes and this was illustrated with the dual promoter used in this study. Apart from circumstances in which really high levels of protein expression are required, our dual promoter should offer an attractive tool for coexpression of two transgenes. In addition, its small size offers an advantage considering the size limitations posed by retroviral vector packaging.
Materials and methods
FV vector construction
The putative promoter sequence was amplified from genomic DNA using primers specific for the intragenic region between the GLA and HNRNPH2 genes and cloned into an intermediate vector (pA2AGloxPpA, DW Russell unpublished data). The plasmid was sequenceverified and used for amplifying the bidirectional promoter with the following primer sets: (1) forward 5 0 -CGACCGGTGGTAATTTTCCTCC-3 0 and reverse 5 0 -C CATCGATTGTCACGGTGACCG-3 0 fitted with AgeI and ClaI sites, respectively, to allow directional cloning in sense to the GLA gene transcription; and (2) forward 5 0 -C CATCGATGGTAATTTTCCTCC-3 0 and reverse 5 0 -CG ACCGGTTGTCACGGTGACCG-3 0 fitted with ClaI and AgeI sites, respectively, to allow directional cloning antisense to the GLA gene transcription. PCR conditions were 94 1C for 4 min, followed by four cycles at 94 1C for 1 min, 53 1C for 1 min, 72 1C for 1 min, and 30 cycles at 94 1C for 1 min, 60 1C for 1 min, 72 1C for 1 min. The product was purified, restriction enzyme-digested, gel purified, and cloned into promoter-less FV vector backbone 36 carrying the EGFP reporter gene downstream.
The resulting constructs pDF-GH-F and pDF-HG-F (with GH denoting the orientation towards the HNRPH2 gene and HG denoting the orientation towards the GLA gene) were sequenced to identify the intact clones. Clones with either promoter orientation were used for FV vector production. To make the dual reporter vector, we first inserted a rabbit b-globin polyA sequence 37 upstream of the FV multiple cloning site and in reverse orientation to the FV transcription unit and then cloned the bidirectional promoter in either genomic orientation. We then cloned the deleted LNGFR gene from plasmid pBBSNF2 0 hmp (a kind gift from R Richards, University of Washington) and generated the final vectors pDFN. GH.F and pDFN.HG.F with N indicating DLNGFR and F the EGFP reporters. The IRES2GFP vector used for the comparison of the new promoter to the IRES2 element was a bicistronic DfPGKgp91pHoxIRES2GFP vector. The results are from more than three independent transduction experiments at low MOIs (1-2) in HeLa and HT1080 cells.
FV vector production and cell line transduction
Foamy virus vector stocks were made by calcium phosphate transfection of vectors and helper plasmids in 293T cells plated on 10-cm dishes as previously described. 38 The cells were treated overnight with 0.5 M sodium butyrate (Sigma Aldrich, Athens, Greece) and replenished with fresh medium the following day. The viral supernatant was concentrated by high-speed centrifugation (47 800 g for 4 h) and either frozen down in 5% dimethyl sulfoxide or used directly for transduction. Vector stock titers were assayed on HeLa cells and titer was expressed as EGFP-transducing units per ml of supernatant after fluorescent-activated cell sorting analysis for EGFP expression. All cell lines were grown in 5% CO 2 , 100% humidified atmosphere using Dulbecco's modified Eagle's medium-glutamine medium supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotics (penicilin-streptomycin) (all from Invitrogen, SanDiego, CA, USA). Cell line transduction was carried out in 6-well plates at MOIs 1-4.
Ex vivo human HSC transduction and mouse transplantation
Human CB CD34 + cells were isolated from total mononuclear cells after gradient centrifugation on Histopaque (Sigma) and hypotonic lysis of red blood cells. Positive selection was carried out using human CD34 + -positive selection cocktail (Miltenyi Biotech, Cologne, Germany) according to the manufacturer's recommendations. Transduction was carried out at MOI 20 for 18-20 h on retronectin-coated plates (TaKaRa Bio, Shiga, Japan) in StemSpan serum-free medium (Stem Cell Technologies, Vancouver, BC, Canada), supplemented with human stem cell factor FLT-3 ligand and human thrombopoietin at 100 ng ml À1 (all from Peprotech, London, UK). For liquid culture, CD34 + cells were expanded for 5-7 days in the presence of the above cytokines. For clonal analysis, transduced CD34 + cells were plated in human Methocult H4434 methylcellulose medium (Stem Cell Technologies) as previously described. 39 The NOD/SCID animals were originally a kind gift from Dr Bonnet (Cancer Research UK, London). They were maintained at our institute's animal facility in 
Transgene expression analysis by flow cytometry
The transduction efficiency of cell lines was determined by flow cytometry for the expression of EGFP and DLNGFR using an anti-NGFR antibody (BD Pharmingen, Athens, Greece). Cell viability was determined using 7AAD (Sigma). We calculated the percentage of cells coexpressing EGFP and DLNGFR using the following equation:
% double positive cells ¼ ðcells co-expressing EGFP and DLNGFRÞ=ðEGFP single positive þ DLNGFR single positive þ EGFP À DLNGFR double posÞ Bone marrow engraftment of animals was analyzed 8-10 weeks after transplantation by flow cytometry. The presence of human cells was detected using a mouse anti-human CD45 antibody, and transgene expression in mature hematopoietic lineages was assessed by staining with anti-human CD33-PE or anti-human CD19-PE (all antibodies from BD Pharmingen). Mouse isotype controls (BD Pharmingen) were also used. Dead cell exclusion was carried out using propidium iodide (Sigma) and data were acquired on BD FACScan (Beckton Dickinson) or on a Beckman Coulter Cytomics FC500 flow cytometer (Beckman Coulter, Fullerton, CA, USA). Fluorescent-activated cell sorting analysis was carried out using CXP analysis software.
Taqman PCR analysis
The vector copy number in the transduced cell lines, human CD34 + cells and bone marrow samples was analyzed by Quantitative TaqMan PCR performed on an ABI Prism 7000 detector (Applied Biosystems, Foster City, CA USA). Amplification of the foamy provirus was carried out using SYBR Green master mix (Applied Biosystems or Stratagene, Amsterdam Zuidoost, The Netherlands) and primers 5 0 -CTGGAATGTTACTCAAA GAGCTGTTT-3 0 and 5 0 -TGGAACAGGATGCTGCATT CT-3 0 . The amount of human and mouse genomic DNA loaded per reaction was adjusted using a primer/probe (VIC dye) for RNase P and primer/probe for rodent GAPDH (VIC dye), respectively (all from Applied Biosystems). Samples were analyzed in duplicate 25-ml reactions. Standards on the basis of different amounts of pDWE37 plasmid (range 2.8-2.8E+05 vector copies) or genomic DNA (0.6-625 ng) of mouse or human origin were also analyzed and their threshold cycle (C t ) values were plotted in standard curves. These were then used to extrapolate the absolute vector copy number and number of cells per reaction, respectively. The FV vector copy number detection limit was B28 copies per reaction, although the lower limit of RNase P or rodent GAPDH detection was in the region of 0.6 ng of human or mouse DNA per reaction.
Analysis of HNRNPH2 and GLA gene expression was performed on cDNA reverse transcribed from total RNA using MMLV RT (Promega, Manheim, Germany) according to the manufacturer's standard protocol. Taqman PCR amplification was carried out using SYBR Green master mix as above and primers HNRNPH2-F: 5 0 -GGG CTTATCCAACCAGTC-3 0 , HNRNPH2-R: 5 0 -TTAGTGC TCCTTCTCTACC-3 0 , GLA-F: 5 0 -AGAGATTCAGAAGG CAGAC-3 0 and GLA-R: 5 0 -GCATCAATGTCGTAGTAT CC-3 0 . The relative expression of GLA over HNRNPH2 expression was calculated using the 2-DDC t method, after correction for the amount of template using GAPDH (forward: 5 0 -GGGAAGCTTGTCATCAATGG-3 0 and reverse: 5 0 -CATCGCCCCACTTGATTTTG-3 0 ).
Statistical analysis
Data were subjected to one-way analysis of variance using SPSS software to assess the significance of differences between means. Individual values from three or more independent experiments were analyzed per cell type.
